Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965742 | 0.89 | CCNC (0.38) | ACHEOPRM1TMEM97SIGMAR1 | |
| SCHEMBL3971870 | 0.77 | RAB9A (0.35) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL3971864 | 0.77 | RAB9A (0.35) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL3966007 | 0.73 | FFAR4 (0.37) | ERN1CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL3965739 | 0.68 | MAPT (0.38) | MEN1KMT2A | |
| SCHEMBL3965744 | 0.68 | MAPT (0.38) | MEN1KMT2A | |
| SCHEMBL3962266 | 0.66 | CCNC (0.38) | ERN1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3962264 | 0.66 | CCNC (0.38) | ERN1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3962205 | 0.65 | MCL1 (0.39) | — | |
| SCHEMBL3683508 | 0.65 | CCNC (0.50) | ACHECYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | ACHE 3542/4885ERN1 4020/4885CYP1A2 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.